JPRN-UMIN000016885已完成未知
Effects of Tapcom Combination Ophthalmic Solution Switched from Tapros 0.0015% and Timoptol XE 0.5% Solutions - Effects of Tapcom Combination Ophthalmic Solution Switched from Tapros and Timoptol XE Solutions
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
Refer to published paper
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •some corneal abnormality or other diseases which may interfere with accurate IOP measurement history of corneal refractive surgery bronchial asthma or a history of the said disease bronchospasm or severe chronic obstructive pulmonary disease cardiac insufficiency, sinus bradycardia, atrioventricular block (II, or III degree) or cardiogenic shock
研究者
相似试验
Unknown
4 期
Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost MonotherapyGlaucomaNCT00442312Genovate Biotechnology Co., Ltd.,43
Unknown
2 期
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil DiameterHealthyNCT02214680Carmel Medical Center25
已完成
不适用
Influence of therapeutic agent for glaucoma on biological clockJPRN-jRCTs071180026Yoshihara Tatsuya16
已完成
4 期
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00061503Alcon Research
Unknown
4 期
Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled TrialGlaucomaCataractNCT00273221National University Hospital, Singapore50